Inventor · disambiguated record
Remy Luthringer
Also filed as: LUTHRINGER REMY · LUTHRINGER REMY HENRI
10 granted patents·24 pending applications·67 citations·filing 2011–2025
89Inventor score
Top patents by PatentIndex Score
34 records- 0194US10799493B2Compositions and methods for treating schizophreniaMINERVA NEUROSCIENCES INC·Filed 2019·Granted Oct 13, 2020·7 cites·20 claims
- 0294US9458130B2Compositions and methods for treating schizophreniaMINERVA NEUROSCIENCES INC·Filed 2015·Granted Oct 4, 2016·20 cites·14 claims
- 0393US9730920B2Compositions and methods for treating schizophreniaMINERVA NEUROSCIENCES INC·Filed 2016·Granted Aug 15, 2017·12 cites·20 claims
- 0492US10258614B2Compositions and methods for treating schizophreniaMINERVA NEUROSCIENCES INC·Filed 2017·Granted Apr 16, 2019·10 cites·34 claims
- 0589US11083723B2Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotectionMINERVA NEUROSCIENCES INC·Filed 2019·Granted Aug 10, 2021·3 cites·20 claims
- 0688US2025195494A1Compositions and methods for treating schizophreniaMINERVA NEUROSCIENCES INC·Filed 2024·Application pending·0 cites
- 0787US12048768B2Gastro-resistant controlled release oral dosage formsMINERVA NEUROSCIENCES INC·Filed 2022·Granted Jul 30, 2024·1 cites·21 claims
- 0886US11464744B2Gastro-resistant controlled release oral dosage formsMINERVA NEUROSCIENCES INC·Filed 2018·Granted Oct 11, 2022·3 cites·12 claims
- 0983US2023201184A1Compositions and methods for treating schizophreniaMINERVA NEUROSCIENCES INC·Filed 2023·Application pending·0 cites
- 1077US9732059B2Methods of use of cyclic amide derivatives to treat schizophreniaLUTHRINGER REMY HENRI·Filed 2011·Granted Aug 15, 2017·11 cites·25 claims
- 1176US2025009665A1Gastro-resistant controlled release oral dosage formsMINERVA NEUROSCIENCES INC·Filed 2024·Application pending·0 cites
- 1275US2023248714A1(2s)-1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy] propan-2-ol or its metabolite for treating anxiety disordersMINERVA NEUROSCIENCES INC·Filed 2023·Application pending·0 cites
- 1373US2025109127A1Methods of use of phenoxypropylamine compounds to treat depressionMINERVA NEUROSCIENCES INC·Filed 2024·Application pending·0 cites
- 1472US2025179044A1Methods of use of cyclic amide derivatives to treat schizophreniaMINERVA NEUROSCIENCES INC·Filed 2024·Application pending·0 cites
- 1571US2021228561A1Compositions and methods for treating schizophreniaMINERVA NEUROSCIENCES INC·Filed 2020·Application pending·0 cites
- 1671US2024376068A1Sigma ligand compounds and uses thereofMINERVA NEUROSCIENCES INC·Filed 2024·Application pending·0 cites
- 1770US2024016790A1Methods of using a phenoxypropylamine compound to treat painMINERVA NEUROSCIENCES INC·Filed 2023·Application pending·0 cites
- 1869US11766430B2Methods of using a phenoxypropylamine compound to treat painMINERVA NEUROSCIENCES INC·Filed 2019·Granted Sep 26, 2023·0 cites·18 claims
- 1967US2023190726A1Compositions and methods for treating negative symptoms in non-schizophrenic patientsMINERVA NEUROSCIENCES INC·Filed 2022·Application pending·0 cites
- 2067US2022096455A1Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotectionMINERVA NEUROSCIENCES INC·Filed 2021·Application pending·0 cites
- 2166US2025235443A1Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotectionMINERVA NEUROSCIENCES INC·Filed 2025·Application pending·0 cites
- 2265US2022274951A1Methods of use of cyclic amide derivatives to treat schizophreniaMINERVA NEUROSCIENCES INC·Filed 2022·Application pending·0 cites
- 2365US2025228837A1(2s)-1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy] propan-2-ol or its metabolite for treating anxiety disordersMINERVA NEUROSCIENCES INC·Filed 2025·Application pending·0 cites
- 2463US2025228838A1Methods of use of cyclic amide derivatives to treat sigma receptor mediated disordersMINERVA NEUROSCIENCES INC·Filed 2025·Application pending·0 cites
- 2562US12006300B2Sigma ligand compounds and uses thereofMINERVA NEUROSCIENCES INC·Filed 2021·Granted Jun 11, 2024·0 cites·41 claims
- 2661US2021106573A1Methods of use of cyclic amide derivatives to treat sigma receptor mediated disordersMINERVA NEUROSCIENCES INC·Filed 2020·Application pending·0 cites
- 2760US2023255953A1Use of roluperidone in preventing relapse in schizophrenia patientsMINERVA NEUROSCIENCES INC·Filed 2023·Application pending·0 cites
- 2855US2019216793A1Compositions and methods for treating negative symptoms in non-schizophrenic patientsMINERVA NEUROSCIENCES INC·Filed 2017·Application pending·0 cites
- 2954US2020223838A1Methods of use of phenoxypropylamine compounds to treat depressionMINERVA NEUROSCIENCES INC·Filed 2020·Application pending·0 cites
- 3051US2018155318A1Methods of use of cyclic amide derivatives to treat schizophreniaMINERVA NEUROSCIENCES INC·Filed 2017·Application pending·0 cites
- 3151US2019183874A1(2s)-1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy] propan-2-ol or its metabolite for treating anxiety disordersMINERVA NEUROSCIENCES INC·Filed 2017·Application pending·0 cites
- 3249US2014206722A1Methods of use of phenoxypropylamine compounds to treat depressionMINERVA NEUROSCIENCES INC·Filed 2014·Application pending·0 cites
- 3346US2016354357A1Methods of use of cyclic amide derivatives to treat sigma receptor mediated disordersMINERVA NEUROSCIENCES INC·Filed 2016·Application pending·0 cites
- 3443US2013274290A1Methods of use of cyclic amide derivatives to treat sigma receptor mediated disordersLUTHRINGER REMY HENRI·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Remy Luthringer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →